Figure 3.

Hazard ratios (95% CIs) for the major bleeding outcome^a by eGFR category; within each eGFR category, warfarin initiation was considered as the reference category in estimating the hazard ratios and their 95% CIs.

Meta-regression showed that the association between rivaroxaban initiation (compared with warfarin initiation) and the safety outcome was not modified by eGFR category (P = 0.76).

^aDefined as the first hospitalization for major bleeding (intracranial, upper or lower gastrointestinal, or other bleeding).

Abbreviations: CI, confidence interval; eGFR, estimated glomerular filtration rate; EXTEND45, Examining Outcomes in Chronic Disease in the 45 and Up Study (data source used in the state of New South Wales, Australia; due to 0 cells [ie, no outcome events] recorded for eGFR categories 45-59 mL/min/1.73 m² and eGFR 30-44 mL/min/1.73 m², data from EXTEND45 were excluded from these eGFR categories; there were no rivaroxaban–warfarin matched pairs included for eGFR <30 mL/min/1.73 m²); PROMIS, Patient Records and Outcome Management Information System (the data source used in the province of British Columbia, Canada; PROMIS is an integrated registry and clinical information system for chronic kidney disease [eGFR <60 mL/min/1.73 m²] and therefore was excluded from eGFR category ≥60 mL/min/1.73 m² group); S, number of outcome events were <5 and cells were suppressed to meet privacy restrictions.